An interventional study of Whole-Breast Radiotherapy Positioning in Breast Cancer and Ductal Carcinoma In Situ, sponsored by Mahidol University. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Mahidol University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).
Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.
In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.
The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.
The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.
This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.
Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.
The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.
The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.
The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.
287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 55 are open to participants now.
This study's planned enrollment of 24 is below the median of 66 across 208 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.
Browse Carcinoma, Intraductal, Noninfiltrating studies →Mahidol University is the lead sponsor of 749 studies on the registry; 121 are open to participants now.
Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability.
Radiation: Whole-Breast Radiotherapy Positioning
Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients.
Mean Heart Dose in Supine Versus Prone Treatment Plans
Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage.
Time frame: within 4 weeks after both CT simulations
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage.
Time frame: within 4 weeks after both CT simulations
PTV_Eval V95 in Supine Versus Prone Treatment Plans
PTV\_Eval V95, defined as the percentage of PTV\_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV\_Eval V95 will be compared between the two positions. The unit of measure is percentage (%).
Time frame: within 4 weeks after both CT simulations
Treatment time from initial setup to treatment completion
Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes.
Time frame: within 4 weeks after treatment completion
translational X Positioning Accuracy
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).
Time frame: within 4 weeks after treatment completion
translational Y Positioning Accuracy
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).
Time frame: within 4 weeks after treatment completion
translational Z Positioning Accuracy
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).
Time frame: within 4 weeks after treatment completion
Patient Satisfaction Score
Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position.
Time frame: within 1 hours after both CT simulations, and within 1 hours after treatment completion
Radiation Therapist Satisfaction
Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique.
Time frame: within 1 hours after treatment completion
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity.
Time frame: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 44 non-industry interventional studies with no phase under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 148. This study's planned 12 months is below that.
Counting every sponsor, half of 47 studies reached it within 69 months; a quarter within 30 and three quarters within 134.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Intraductal, Noninfiltrating →